Five Prime Therapeutics Inc  

(Public, NASDAQ:FPRX)   Watch this stock  
Find more results for FPRX
47.51
-1.11 (-2.28%)
After Hours: 47.51 0.00 (0.00%)
Jan 17, 4:39PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 46.58 - 48.45
52 week 28.01 - 60.98
Open 48.18
Vol / Avg. 0.00/404,259.00
Mkt cap 1.32B
P/E 6.18
Div/yield     -
EPS 7.69
Shares 28.44M
Beta 4.40
Inst. own 96%
Mar 8, 2017
Q4 2016 Five Prime Therapeutics Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Nov 7, 2016
Five Prime Therapeutics Inc at Credit Suisse Healthcare Conference
Nov 3, 2016
Q3 2016 Five Prime Therapeutics Inc Earnings Call
Nov 3, 2016
Q3 2016 Five Prime Therapeutics Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin -290.63% 65.73%
Operating margin -394.55% 75.56%
EBITD margin - 76.00%
Return on average assets -16.17% 70.93%
Return on average equity -18.75% 96.31%
Employees 154 -
CDP Score - -

Address

2 Corporate Dr
SOUTH SAN FRANCISCO, CA 94080-7047
United States - Map
+1-415-3655600 (Phone)
+1-415-3655601 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Five Prime Therapeutics, Inc. (Five Prime) is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company has three product candidates in clinical development covering multiple potential indications. It focuses on immuno-oncology, an area in which it has clinical and discovery programs, and product and discovery collaborations. The Company seeks to engage third-party collaborators to assist it in developing companion diagnostics for its clinical programs. The Company's product candidates include FPA008, FPA144 and FP-1039/GSK3052230. The FPA008 is an antibody that inhibits colony stimulating factor-1 (CSF1), receptor (CSF1R). The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b (FGFR2b). FP-1039 is a protein therapeutic designed to trap and neutralize cancer-promoting fibroblast growth factors (FGFs).

Officers and directors

Lewis T. Williams M.D. Ph.D. Chairman of the Board, President, Chief Executive Officer
Age: 66
Bio & Compensation  - Reuters
Marc L. Belsky Chief Financial Officer, Senior Vice President
Age: 60
Bio & Compensation  - Reuters
Aron M. Knickerbocker Chief Operating Officer, Principal Operating Officer, Executive Vice President, Director
Age: 46
Bio & Compensation  - Reuters
Francis Willard Sarena J.D. Executive Vice President, General Counsel, Secretary
Age: 45
Bio & Compensation  - Reuters
Mark D. McDade Lead Independent Director
Age: 60
Bio & Compensation  - Reuters
Kapil Dhingra Director
Age: 56
Bio & Compensation  - Reuters
Sheila Gujrathi M.D. Director
Age: 45
Bio & Compensation  - Reuters
William R. Ringo Jr. Director
Age: 70
Bio & Compensation  - Reuters
Franklin M. Berger Independent Director
Age: 66
Bio & Compensation  - Reuters